filgotinib (Jyseleca)

From Aaushi
Jump to navigation Jump to search

Indications

Dosage

  • 100 mg or 200 mg PO QD

Adverse effects

Mechanism of action

Notes

  • Galapagos sole developer[2]

More general terms

References

  1. Genovese MC, Kalunian K, Gottenberg JE et al Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease- Modifying Antirheumatic Drug TherapyThe FINCH 2 Randomized Clinical Trial. JAMA. 2019;322(4):315-325 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31334793 https://jamanetwork.com/journals/jama/fullarticle/2738551
    Singh JA Filgotinib, a JAK1 Inhibitor, for Treatment-Resistant Rheumatoid Arthritis. JAMA. 2019;322(4):309-311 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31334773 https://jamanetwork.com/journals/jama/fullarticle/2738528
  2. 2.0 2.1 2.2 2.3 Gever J Filgotinib Maintains RA Efficacy for 3 Years, No New Safety Issues. Looks like FDA blew the call on selective JAK1 inhibitor. MedPage Today October 28, 2024 https://www.medpagetoday.com/rheumatology/arthritis/112618

Database